HYPERION sotatercept study has positive results, stops early

PHA Canada
Feb 10, 2025
1 min read

The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial hypertension reduced the risk of disease progression. The trial was stopped early so all patients in the trial, including those in the placebo arm, can benefit from sotatercept. Patients in the trial will be able to receive sotatercept through the ongoing SOTERIA extension study.

Study results have not yet been published.

Read the press release here

Recent Posts

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

Comments